8/15/2013 7:20:14 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Buyout talks over Amgen Inc. (AMGN)’s proposed takeover of Onyx Pharmaceuticals Inc. (ONXX) are held up over a dispute about access to data from an ongoing drug trial even as the two sides have a general agreement on price, said three people familiar with the matter. Onyx is prepared to accept a $130-a-share all-cash offer and Amgen remains interested, the people said. At issue is whether Onyx will provide Amgen with data from a study designed for European approval of Onyx’s blood-cancer treatment Kyprolis, said two of the people, who asked not to be named because the discussions are private.
Help employers find you! Check out all the jobs and post your resume.
comments powered by